Literature DB >> 1616910

In vivo metabolism of apolipoprotein A-I in a patient with homozygous familial hypercholesterolemia.

J R Schaefer1, D J Rader, K Ikewaki, T Fairwell, L A Zech, M R Kindt, J Davignon, R E Gregg, H B Brewer.   

Abstract

Familial hypercholesterolemia (FH), caused by a defect in the low density lipoprotein (LDL) receptor, results in high plasma concentrations of LDL cholesterol due to both overproduction and delayed catabolism of LDL. FH is also associated with significantly lower levels of plasma high density lipoprotein cholesterol and apolipoprotein (apo) A-I in both heterozygous and homozygous patients. However, the metabolic basis of the hypoalphalipoproteinemia in FH has not been elucidated. We investigated the kinetics of apo A-I in a homozygous FH patient and two normal control subjects by using endogenous labeling with a stable isotopically labeled amino acid. Study subjects were administered a primed constant infusion of 13C6-phenylalanine for 12 hours. Apolipoproteins were isolated from plasma drawn at selected time points and analyzed for their isotopic enrichment by gas chromatography-mass spectrometry. The fractional catabolic rate of apo A-I in the FH subject was found to be substantially increased (0.38 day-1) compared with that of the normal subjects (mean, 0.26 day-1). In addition, the apo A-I production rate was decreased in the FH subject (6.5 mg/kg.day-1) compared with the normal subjects (mean, 11.1 mg/kg.day-1). In conclusion, the low levels of high density lipoprotein cholesterol and apo A-I in this homozygous FH patient are due to the combined metabolic defects of increased apo A-I catabolism and decreased apo A-I production.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1616910     DOI: 10.1161/01.atv.12.7.843

Source DB:  PubMed          Journal:  Arterioscler Thromb        ISSN: 1049-8834


  8 in total

1.  LDL-apheresis depletes apoE-HDL and pre-β1-HDL in familial hypercholesterolemia: relevance to atheroprotection.

Authors:  Alexina Orsoni; Samir Saheb; Johannes H M Levels; Geesje Dallinga-Thie; Marielle Atassi; Randa Bittar; Paul Robillard; Eric Bruckert; Anatol Kontush; Alain Carrié; M John Chapman
Journal:  J Lipid Res       Date:  2011-09-26       Impact factor: 5.922

2.  Reference distributions for apolipoproteins AI and B and B/AI ratios: comparison of a large cohort to the world's literature.

Authors:  Robert F Ritchie; Glenn E Palomaki; Louis M Neveux; Thomas B Ledue; Santica Marcovina; Olga Navolotskaia
Journal:  J Clin Lab Anal       Date:  2006       Impact factor: 2.352

Review 3.  Reverse Cholesterol Transport Dysfunction Is a Feature of Familial Hypercholesterolemia.

Authors:  Joan Carles Escolà-Gil; Noemí Rotllan; Josep Julve; Francisco Blanco-Vaca
Journal:  Curr Atheroscler Rep       Date:  2021-04-29       Impact factor: 5.113

4.  Lipoprotein kinetics in male hemodialysis patients treated with atorvastatin.

Authors:  Johannes P Schwaiger; Yoshinobu Nakada; Ramona Berberich; Katsunori Ikewaki; Benjamin Dieplinger; Emanuel Zitt; Ulrich Neyer; Hermann Salmhofer; Florian Kronenberg; Paul Koenig; Hans Dieplinger
Journal:  Clin J Am Soc Nephrol       Date:  2013-04-18       Impact factor: 8.237

5.  Markedly accelerated catabolism of apolipoprotein A-II (ApoA-II) and high density lipoproteins containing ApoA-II in classic lecithin: cholesterol acyltransferase deficiency and fish-eye disease.

Authors:  D J Rader; K Ikewaki; N Duverger; H Schmidt; H Pritchard; J Frohlich; M Clerc; M F Dumon; T Fairwell; L Zech
Journal:  J Clin Invest       Date:  1994-01       Impact factor: 14.808

6.  Cardiovascular risk assessment of dyslipidemic children: analysis of biomarkers to identify monogenic dyslipidemia.

Authors:  Ana Margarida Medeiros; Ana Catarina Alves; Pedro Aguiar; Mafalda Bourbon
Journal:  J Lipid Res       Date:  2014-03-13       Impact factor: 5.922

7.  Serum Anti-Apo B Antibody Level as Residual CVD Marker in DM Patients under Statin Treatment.

Authors:  Hiroyasu Yamamoto; Mari Kawamura; Ikoi Kochi; Minami Imai; Yukie Murata; Toshinobu Suzuki; Yingchao Chen; Kunihiko Hashimoto; Shinji Kihara
Journal:  J Atheroscler Thromb       Date:  2019-03-14       Impact factor: 4.928

8.  Analysis of HDL-microRNA panel in heterozygous familial hypercholesterolemia subjects with LDL receptor null or defective mutation.

Authors:  Roberto Scicali; Antonino Di Pino; Chiara Pavanello; Alice Ossoli; Arianna Strazzella; Antonia Alberti; Stefania Di Mauro; Alessandra Scamporrino; Francesca Urbano; Agnese Filippello; Salvatore Piro; Agata Maria Rabuazzo; Laura Calabresi; Francesco Purrello
Journal:  Sci Rep       Date:  2019-12-30       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.